Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)

NCT07712588 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

880

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma (DLBCL)

Interventions

DRUG: Birelentinib
DRUG: Rituximab
DRUG: Cyclophosphamid
DRUG: Doxorubicin
DRUG: Vincristine
DRUG: Prednisone
DRUG: Placebo

Sponsor

Dizal Pharmaceuticals